Latest B-cell chronic lymphocytic leukemia Stories
WHITE PLAINS, N.Y., July 23, 2014 /PRNewswire-USNewswire/ -- Today's U.S.
-COMMUNITY LEADERS RAISED $30.5 MILLION TO HELP FIND CANCER CURES- WHITE PLAINS, N.Y., July 17, 2014 /PRNewswire/ -- A Chicago man and Los Angeles woman raised $386,284 and $343,962,
LONDON, July 9, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:
- Designation supports the advancement of CTL019 to help address the unmet need of patients with relapsed/refractory acute lymphoblastic leukemia (r/r ALL) EAST HANOVER, N.J., July 7, 2014
Engineered Cells Known As CTL019 Are the First Therapy of Their Kind to Obtain Designation PHILADELPHIA, July 7, 2014 /PRNewswire/ -- A University of Pennsylvania-developed personalized
Breakthrough Designation Reinforces Significant Unmet Need in the Treatment of This Highly Aggressive Cancer THOUSAND OAKS, Calif., July 1, 2014 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced
Robotic Surgery Pioneer, Bob Duggan Now Leading Innovative Biotech Company SUNNYVALE, Calif., June 13, 2014 /PRNewswire-iReach/ --
SUNNYVALE, Calif., June 9, 2014 /PRNewswire/ -- Pharmacyclics, Inc. (Nasdaq: PCYC) today announced that the U.S.
In-demand research report “Chronic Lymphocytic Leukaemia: KOL Insight” worked out by FirstWord is now available at MarketPublishers.com. London, UK (PRWEB)
In a head-to-head comparison of two Food and Drug Administration-approved drugs for the treatment of relapsed chronic lymphocytic leukemia (CLL), ibrutinib significantly outperformed ofatumumab as a second-line therapy.
- An uxorious, effeminate, or spiritless man.
- A timorous, cowardly fellow.